Tony Mok
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.01%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 448
- Lung Cancer Diagnosis and Treatment 104
- Oncology 391
- Lung Cancer Research Studies 152
- Colorectal Cancer Treatments and Studies 119
- Cancer Immunotherapy and Biomarkers 95
- HER2/EGFR in Cancer Research 40
- Co-authors
- Yi‐Long Wu (160 shared papers)James Chih‐Hsin Yang (78 shared papers)Solange Peters (51 shared papers)Federico Cappuzzo (35 shared papers)Alison Armour (5 shared papers)Sumitra Thongprasert (15 shared papers)Masahiro Fukuoka (11 shared papers)Haiyi Jiang (7 shared papers)
- Journals
- Journal of Clinical Oncology (141 papers)Annals of Oncology (116 papers)Journal of Thoracic Oncology (88 papers)Lung Cancer (34 papers)Cancer (16 papers)
- Partner nations
- Hong KongChinaUnited States
In The Last Decade
Tony Mok
667 papers receiving 57.4k citations
Tony Mok's Hit Papers
Peers
Comparison fields: 5 of 169
- Pulmonary and Respiratory Medicine 34.7k
- Oncology 25.6k
- Cancer Research 9.5k
- Hepatology 3.3k
- Molecular Biology 13.4k
Countries citing papers authored by Tony Mok
This map shows the geographic impact of Tony Mok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tony Mok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tony Mok more than expected).
Fields of papers citing papers by Tony Mok
This network shows the impact of papers produced by Tony Mok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tony Mok. The network helps show where Tony Mok may publish in the future.
Co-authors
The 25 scholars most cited alongside Tony Mok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 692 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Hit paper breakdown → | 2009 | 6539 |
| 2 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Hit paper breakdown → | 2007 | 3694 |
| 3 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Hit paper breakdown → | 2013 | 2516 |
| 4 | Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer Hit paper breakdown → | 2016 | 2453 |
| 5 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer Hit paper breakdown → | 2014 | 2407 |
| 6 | Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 1687 |
| 7 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 1634 |
| 8 | Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) Hit paper breakdown → | 2011 | 1216 |
| 9 | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Hit paper breakdown → | 2008 | 1027 |
| 10 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 890 |
| 11 | Non-small-cell lung cancer Hit paper breakdown → | 2015 | 791 |
| 12 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Hit paper breakdown → | 2015 | 734 |
| 13 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Hit paper breakdown → | 2019 | 703 |
| 14 | First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2020 | 683 |
| 15 | Management of non-small-cell lung cancer: recent developments Hit paper breakdown → | 2013 | 599 |
| 16 | Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis Hit paper breakdown → | 2016 | 597 |
| 17 | De-novo and acquired resistance to immune checkpoint targeting Hit paper breakdown → | 2017 | 581 |
| 18 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) Hit paper breakdown → | 2021 | 526 |
| 19 | Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients Hit paper breakdown → | 2015 | 516 |
| 20 | Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab Hit paper breakdown → | 2008 | 493 |
About Tony Mok
Tony Mok is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Hepatology, having authored 692 papers that have together received 58.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (448 papers), Lung Cancer Research Studies (152 papers), Colorectal Cancer Treatments and Studies (119 papers), Lung Cancer Diagnosis and Treatment (104 papers), Cancer Immunotherapy and Biomarkers (95 papers), Cancer Genomics and Diagnostics (90 papers), HER2/EGFR in Cancer Research (40 papers) and Hepatocellular Carcinoma Treatment and Prognosis (39 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (34.7k citations), Oncology (25.6k citations), Cancer Research (9.5k citations), Hepatology (3.3k citations) and Molecular Biology (13.4k citations). Tony Mok has collaborated with scholars based in Hong Kong, China and United States. Frequent co-authors include Yi‐Long Wu, James Chih‐Hsin Yang, Solange Peters, Federico Cappuzzo, Alison Armour, Sumitra Thongprasert, Masahiro Fukuoka, Haiyi Jiang, Nagahiro Saijo and Emma Duffield. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.